April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- Session: Course Correction—Negotiating Payor Rates in the ASC Setting
- Session: Modernizing OR Scheduling—How Northwell Health Streamlined Block Management
- Session: Anchoring Profits—Restructuring Inventory Practices to Secure $200 Million in Cost Savings
- Session: All Hands-on-Deck—How to Justify Your Staffing Needs and FTEs
- Session: Setting Sail—Top 5 Business Trends for Ambulatory Surgery Centers in 2025
- Opening Keynote: Charting Your Course to Success—Financial Wins through Value-Based Performance
- Pre-Conference Workshop: Foundational Leadership Practicum Certificate of Mastery
- Healthcare employment up in January
- OR Business Management Conference, daily coverage begins
- Healthgrades names best hospitals for patient outcomes
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement